Real-world analysis of autologous stem cell transplantation in primary central nervous system lymphoma using Taiwan Blood and Marrow Transplantation Registry
High-dose chemotherapy and stem cell transplant for rare brain lymphomas achieves good survival even without a specific standard drug, offering real-world alternatives.
A retrospective analysis of 65 PCNSL patients from the Taiwan BMTR found HDC/ASCT achieved 2-year OS of 67.4% and 76.0% in frontline and salvage settings respectively. Non-thiotepa conditioning regimens demonstrated comparable efficacy to thiotepa-based protocols, providing real-world evidence supporting non-thiotepa alternatives in institutions with limited thiotepa access.
What the study was
- Study design
- Retrospective registry analysis (n=65, Taiwan BMTR 2012-2022)
- Population
- 65 PCNSL patients in Taiwan BMTR undergoing HDC/ASCT (2012-2022)
- Sample size
- 65
- Category
- Treatment Innovation
- Maturity
- Validated
- Journal
- J Formos Med Assoc
Why it surfaced
Registry-level real-world evidence for ASCT in PCNSL from Asian population; non-thiotepa conditioning comparability has practical global relevance; n=65 limits confidence.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.